why is the fda banning compounded semaglutide Fifth Circuit probes ban on GLP-1s FDA moves to remove GLP-1

( 10.1056/NEJMoa2107519) [DOI] [PubMed] [Google Scholar] Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, et al

CVS dropped Eli Lillys obesity drug Zepbound from the list of medicines it covers for reimbursement

Where each stands and what the data shows The reported results put them in a rough order on efficacy, though cross-trial comparisons are not definitive

In fact, hair loss rates after bariatric surgery are often higher than those seen with GLP-1 therapy, with some studies reporting rates of 30-40% in the first year post-surgery

They reduced their training volume without abandoning intensity